연구 개발 영역의 진화, 기술의 진보, 연구자의 지식 뱅크 증가에 수반하여, 많은 질병의 발병이나 진행에 중심적인 역할을 하는 단백질이 많이 발견되고 있습니다. 그 중에서도 면역체크포인트 단백질은 항암 면역반응을 억제하는 역할을 담당하고 있기 때문에 주목받아 유망한 치료 표적으로서 부상해 왔습니다. VISTA 단백질은 발견된 가장 새로운 체크포인트 단백질 중 하나이며, 다른 체크포인트 단백질과는 다른 특별한 성질을 가짐으로써 암과 염증성 질환 모두의 치료에서 가능성을 나타냅니다. 했습니다. 그 결과, VISTA는 여러 연구의 대상이 되고 있으며, 제약회사는 VISTA를 표적으로 한 약제의 개발로 이러한 노력을 보완하고 있습니다.
V-domain Ig suppressor of T cell activation, 통칭 VISTA는 면역체크포인트 단백질의 하나로 면역계에 대한 억제작용과 자극작용을 모두 발휘합니다. 확인된 다른 면역 체크포인트는 면역 반응을 부정적으로 조절하는 것으로 알려져 있으며, 후자가 VISTA를 독특한 존재로 만드는 이유입니다. VISTA의 억제 기능을 저해하는 것은 암 치료에 있어서 주목할 만한 접근으로서 부상하고 있는 한편, VISTA의 면역계 자극 기능은 마우스 모델로 널리 연구되고 있습니다.
이러한 조사 연구를 기반으로 제약 회사와 생명 공학 기업이 주로 암 치료를 위해 VISTA를 표적으로 한 치료 개입의 개발에 주력하고 있습니다. 그러나 이 분야에 과제가 없었던 것은 아니며, 많은 과제가 임상 개발에서 중단되었습니다. 그러나 새로운 세대의 VISTA 억제제는 이러한 후보의 단점을 해결하기 위해 개발되었습니다.
이 보고서는 세계의 VISTA 억제제 시장을 조사했으며, 시장 개요와 함께 약물 동향, 임상시험 동향, 지역별 동향 및 시장 진출기업경쟁 구도 등을 제공합니다.
Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2024 Report Highlights:
With evolution in the research and development domain, along with technological advancements and the increasing knowledge bank of researchers, a number of proteins have been discovered to play central roles in development and progression of many diseases. Among these, immune checkpoint proteins have especially gained attention for their role in suppressing anti-cancer immune responses and have emerged as promising therapeutic targets. The VISTA protein is one of the newest checkpoint proteins to be discovered, which has showed potential in treating both cancer and inflammatory diseases because of its extraordinary properties that make it different from its fellow checkpoint proteins. As a result, it has become the subject of several research studies, with pharmaceutical companies complementing these efforts with the development of drugs targeting VISTA.
V-domain Ig suppressor of T cell activation, commonly known as VISTA, is an immune checkpoint protein which exerts both inhibitory and stimulatory effects on the immune system. Other identified immune checkpoints are only known to negatively regulate immune responses, which is why the latter makes VISTA unique. Blocking its inhibitory functions has emerged as a hot approach in the treatment of cancer, while its immune system stimulatory functions have been explored widely in murine models.
With these research studies serving as the foundation, several pharmaceutical and biotechnology companies have been focusing on the development of therapeutic interventions that target the VISTA, mainly for the management of cancer, given that most clinical studies were conducted to elucidate its role in cancer. However, the field has not been without challenges, with many candidates being withdrawn from clinical development. However, new generation VISTA inhibitors are being developed to address the shortcomings of these candidates.
CA-170, developed by Aurigene Oncology and Curis, marks a significant advancement in the landscape of VISTA-targeted therapies. CA-170 is a first-in-class oral small molecule that directly targets both PD-1/PD-L1 and VISTA pathways. It is currently undergoing phase 2/3 clinical trials in India for the management of non-squamous non-small cell lung cancer, making it the candidate farthest ahead in the pipeline of VISTA-targeted therapies. While CA-170 has shown anti-tumor activity in multiple preclinical models, results from these ongoing clinical trials are yet to be revealed by Aurigene or Curis.
In addition to Aurigene and Curis, several research institutes, and biotechnology and pharmaceutical companies are actively pursuing VISTA inhibitors; these include Cancer Prevention and Research Institute of Texas, Kineta, Sensei Biotherapeutics, Washington University among others. Therefore, the current market for VISTA targeted therapies is witnessing a high level of competition and innovation, albeit with smaller companies dominating and larger companies waiting for breakthroughs before making their way into the market.
At present, cancer, mainly solid tumors, are dominating the research and development landscape of VISTA-targeted therapies. However, ongoing research has also associated the functions of VISTA with autoimmune and inflammatory disorders, wherein aberrant immune system activation damages tissue. This can however, with averted with the use of VISTA agonists, which can help expand the potential of VISTA as a therapeutic target to diseases mediated by the immune system. Additionally, modulation of VISTA activity has also been linked to viral infection through research findings indicating the VISTA plays a role in regulating the immune responses in viral infections. Therefore, as research findings continue linking VISTA functions to new indications, it becomes increasingly evident that researchers are yet to unravel the complexities of VISTA.
In conclusion, the landscape of VISTA-targeted therapeutics is characterized by active research, early-stage clinical development, and growing interest from both the scientific community and the pharmaceutical sector. As research progresses, VISTA inhibitors emerge as a beacon of innovation, holding up hope not only for cancer treatments but also for viral infections, autoimmune illnesses, and other ailments.